Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease

(Downloading may take up to 30 seconds. If the slide opens in your browser, select File -> Save As to save it.)

Click on image to view larger version.

Figure 2.
Figure 2.

SOST transgenic expression has a negative impact on bone parameters. (A) Body weight measurements of 5-mo-old male mice (non-tg = 13; SOSTwt = 15; SOSTvbΔ = 14; animals were pooled from two lines of SOSTwt and two lines of SOSTvbΔ; Supplemental material). (B) Bone mineral density in the tibia, femur, and lumbar spine as evaluated by DEXA. (C) Bone volume, trabecular number, thickness, and separation as evaluated in the cancellous bone compartment of the proximal tibia metaphysis by microCT. Mean ± SEM; (*) p < 0.05 vs. non-tg.

This Article

  1. Published in Advance June 17, 2005, doi: 10.1101/gr.3437105 Genome Res. 15: 928-935

Preprint Server



Current Issue

  1. February 2026, 36 (2)
  1. Current Issue
  1. Alert me to new issues of Genome Research